NeuroVive announces prospectus regarding admission to trading of new shares

The prospectus regarding the admission to trading of newly issued shares in
NeuroVive Pharmaceutical AB (publ) is now available on the company’s website
www.neurovive.se and in the company’s offices, at Medicon Village, Scheelevägen
2, 223 81 Lund. Documents incorporated by reference in the prospectus are also
available in accordance with the above.
The prospectus has been prepared due to the admission to trading of the
1,647,059 new shares in NeuroVive, that were issued in connection with the
directed share issue to a limited group of institutional US investors, which was
resolved upon on May 8, 2015. The newly issued shares are expected to be
admitted to trading on Nasdaq Stockholm on or about May 19, 2015.

About NeuroVive
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(myocardial infarct) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include development of treatments against brain injury in stroke
patients, and drug substances for cellular protection and treatment of
mitochondrial disorders causing energy deficiency. NeuroVive’s shares are listed
on Nasdaq, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se (http://file///C:/NRPortbl/LEGAL/SMNILSSO/ww
w 
.neurovive.se)

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under the Swedish Securities Market Act. The information was
submitted for publication on May 18, 2015, at 8.00 p.m. CET.

Important information
Publication or distribution of this press release in certain jurisdictions may
be subject to restrictions according to law and the people in jurisdictions
where this press release has been made public or distributed should inform
themselves and follow such local restrictions. This press release does not
contain and does not constitute or form part of an invitation to acquire or
subscribe or a solicitation of any offer to buy or subscribe for shares,
subscription rights or other securities in NeuroVive.

This press release may not be published or distributed, directly or indirectly,
in or into the US, Canada, Japan, Hong Kong, New Zeeland, South Africa,
Australia or in any other jurisdiction where such distribution would be
prohibited by applicable law. The information in this press release may not be
redistributed, reproduced or passed on in ways that conflict with applicable
restrictions. Failure to comply with these restrictions may constitute a
violation of the United States Securities Act of 1933 (“Securities Act”) or
applicable laws of other jurisdictions.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)